RxDoctor Payments Data

Trisha Burns

Psychiatric/Mental Health · Jonesboro, ARNPI 1639654213

Payments from drug & device makers

$2,206in general payments, 2019–2025

Across 125 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$831
  • Johnson & Johnson$502
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$244
  • Otsuka America Pharmaceutical, Inc.$175
  • Neurocrine Biosciences, Inc.$130
  • Lundbeck LLC$101
  • plus $223 from 7 others

What the payments were for

  • Food & beverage$2,15998%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,206 in reported general payments places this provider in the 75th percentile of 359 psychiatric/mental health providers in Arkansas.

See all psychiatric/mental health providers in Arkansas

Medicare billing

Part B allowed, 2024
$26,761
Medicare patients
33
Services billed
379

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl23$27,274
Hydroxyzine Hcl51$1,608
Buspirone Hcl100$1,199
Aripiprazole49$912
Desvenlafaxine Succinate ErDesvenlafaxine Succinate26$866
Duloxetine Hcl58$797
Lamotrigine69$769
Oxcarbazepine32$662
Divalproex Sodium ErDivalproex Sodium12$620
Phenelzine Sulfate11$596
Trazodone Hcl44$395
Fluoxetine Hcl79$354
Venlafaxine Hcl ErVenlafaxine Hcl22$334
Quetiapine Fumarate46$286
Divalproex Sodium20$164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$502$27,27423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 359 psychiatric/mental health providers in Arkansas.

Other psychiatric/mental health in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →